Which statement best describes the primary goal of phase II clinical trials in oncology when evaluating a new agent?

• A. Maximum tolerated dose of an individual drug or combination of drugs and to identify dose-limiting toxicities.
• B. The efficacy of a new agent in relation to a standard existing treatment.
• C. The optimal dosing schedule for investigational drugs.
• D. The efficacy of a new agent in the treatment of specific types of cancer and to validate toxicity and dosage data.

Answer: (D)

Phase II trials focus on whether the new agent shows meaningful activity in a defined cancer type while continuing to verify safety at the studied dose. After Phase I identifies a dose that patients can tolerate, Phase II tests the agent in a specific tumor population to see if there is real evidence of efficacy (such as objective responses or progression-free survival) and to confirm the safety profile and dosing in a larger group. This work helps decide whether to move on to a definitive Phase III trial that would compare the new agent against standard therapy. The other options describe objectives more typical of Phase I (finding the maximum tolerated dose and dose-limiting toxicities) or scenarios about dosing schedules or direct comparisons to standard treatment, which are not the primary aim of Phase II.